SubsidieMeestersintegrated nano-photonic OMICs bio-SENSor for lung cancer
OMICSENS aims to develop a novel nano-photonic omics bio-sensor for real-time detection of TKI resistance in NSCLC, enhancing prognosis and paving the way for personalized cancer treatment.
Projectdetails
Introduction
OMICSENS aims to develop a radically new omics measurement platform that would be initially applied to improve non-small cell lung cancer (NSCLC) prognosis by ensuring a timely and accurate detection of Tyrosine Kinase Inhibitor (TKI) resistance associated with Epidermal Growth Factor Receptor (EGFR) mutations. Subsequently, OMICSENS will be used to improve the prognosis of patients suffering from other types of cancers.
Objectives
OMICSENS targets the creation of the first nano-photonic integrated omics bio-sensor to tackle TKI resistance and improve NSCLC treatment outcomes and patient prognosis.
Technology Overview
Thanks to OMICSENS, we will build a six-layer technology comprised of:
- An on-chip embedded infrared source array
- An artificial intelligence optimized nano-structured surface for photonic signal enhancement
- A functionalized surface of high absorbance to specific analytes
- A microfluidics system to deliver the sample
- A metamaterial-based photo detector array with optimized quantum efficiency
- An AI algorithm enabling analyte quantification
Our miniaturized omics bio-sensor will enable real-time and concurrent measurements of omics, compatible with organ-on-chip (OOC) in the future.
Future Applications
OOC is one of the most promising bioengineering developments, paving the way to more efficient drug testing and personalized medicine through digital twinning of a biological system. However, OOC is lacking a real-time, integrated bio-sensing technology. OMICSENS proposes a disruptive bio-sensor to bridge this gap.
Impact on Healthcare
OMICSENS will create a radically new device useful for telehealth, capable of improving medical diagnostics while fostering a patient-centered approach.
Consortium
To achieve our novel and ambitious objective, we have brought together an interdisciplinary consortium of top-level academics (LMU, UNITN, IBEC, KTH) and SMEs (MW, QAI, 4K-MEMS), including expertise in:
- Oncology
- Bio-engineering
- Micro-fluidics
- Biochemistry
- MEMS
- Nano-photonics
- Computational physics
- Artificial intelligence
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.372.318 |
| Totale projectbegroting | € 2.372.318 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI TRENTOpenvoerder
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
- MULTIWAVE TECHNOLOGIES
- FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
- KUNGLIGA TEKNISKA HOEGSKOLAN
- 4K-MEMS SA
- QUAISR LIMITED
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technologyDISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI. | EIC Pathfinder | € 3.018.312 | 2022 | Details |
In-situ & operando organiC electrochemical transistors monitored by non-destructive spectroscopies for Organic cmos-like NeuromorphIc CircuitsICONIC aims to advance implantable AI organic electronic devices for chronic disease management by investigating PMIECs, leading to smart drug-delivery systems with enhanced accuracy and safety. | EIC Pathfinder | € 2.664.940 | 2024 | Details |
Multivariate optoacoustic sensor for longitudinal diabetes monitoringMOSAIC aims to develop a portable, non-invasive optoacoustic sensor powered by explainable AI to monitor diabetes, enhancing early detection and treatment while reducing healthcare costs. | EIC Pathfinder | € 2.997.921 | 2025 | Details |
NEW TECHNOLOGY FOR 1 MICRON RESOLUTION BIOMEDICAL IMAGINGThe 1MICRON project aims to revolutionize cancer detection by developing high-resolution, integrated x-ray sensors for immediate surgical feedback, potentially saving over 100,000 treatments annually in Europe. | EIC Pathfinder | € 2.999.999 | 2025 | Details |
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENTMULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care. | EIC Pathfinder | € 2.863.733 | 2024 | Details |
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology
DISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI.
In-situ & operando organiC electrochemical transistors monitored by non-destructive spectroscopies for Organic cmos-like NeuromorphIc Circuits
ICONIC aims to advance implantable AI organic electronic devices for chronic disease management by investigating PMIECs, leading to smart drug-delivery systems with enhanced accuracy and safety.
Multivariate optoacoustic sensor for longitudinal diabetes monitoring
MOSAIC aims to develop a portable, non-invasive optoacoustic sensor powered by explainable AI to monitor diabetes, enhancing early detection and treatment while reducing healthcare costs.
NEW TECHNOLOGY FOR 1 MICRON RESOLUTION BIOMEDICAL IMAGING
The 1MICRON project aims to revolutionize cancer detection by developing high-resolution, integrated x-ray sensors for immediate surgical feedback, potentially saving over 100,000 treatments annually in Europe.
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT
MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
DETACT - Detection of Enzymes and muTAtions for Cancer TreatmentCytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen. | Mkb-innovati... | € 215.845 | 2019 | Details |
On-demand COMmunication between fluorescent organic nanoparticles through Energy TransferThe COMET project aims to develop innovative optical biosensors using communicating fluorescent organic nanoparticles for real-time detection of opioids in complex biological media. | ERC Starting... | € 1.500.000 | 2023 | Details |
In vivo Immunofluorescence-Optical Coherence TomographyDevelop a high-resolution endoscopic imaging system combining Optical Coherence Tomography and fluorescent antibodies for improved diagnosis and treatment of esophageal cancer and lung disease. | ERC Advanced... | € 2.500.000 | 2025 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
DETACT - Detection of Enzymes and muTAtions for Cancer Treatment
Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.
On-demand COMmunication between fluorescent organic nanoparticles through Energy Transfer
The COMET project aims to develop innovative optical biosensors using communicating fluorescent organic nanoparticles for real-time detection of opioids in complex biological media.
In vivo Immunofluorescence-Optical Coherence Tomography
Develop a high-resolution endoscopic imaging system combining Optical Coherence Tomography and fluorescent antibodies for improved diagnosis and treatment of esophageal cancer and lung disease.